🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are increasing worldwide, with data suggesting in excess of 82 million infections annually. Particularly high rates are seen in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of growing infection rates, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in December for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization represents a significant shift in the management of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Results and Worldwide Availability

As per findings detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an equal footing with the existing first-line therapy, which uses an injection and a pill. The research enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have voiced optimism. Having a single-dose, oral treatment like this is hailed as a "game-changer" for public health efforts. This is viewed as essential to reduce the burden of the illness for people and to stop the proliferation of untreatable gonorrhoea globally.